Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fludarabine + thiotepa + melphalan + anti-thymocyte globulin
- Development stage
- Unknown
- Lead developer
- University Hospital Tuebingen
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This is a reduced-intensity conditioning (RIC) regimen developed by the University Hospital Tuebingen for patients undergoing haploidentical hematopoietic stem cell transplantation (HCT). The protocol is specifically designed for high-risk patients with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) in complete remission who lack a matched donor. It combines three chemotherapy agents—fludarabine (a purine analog), thiotepa, and melphalan (both alkylating agents)—with Thymoglobuline (anti-thymocyte globulin), a polyclonal antibody used for T-cell depletion. This combination aims to provide sufficient immunoablation and myeloablation to allow for the engraftment of CD3/CD19-depleted stem cell grafts while minimizing regimen-related toxicity compared to standard myeloablative conditioning.
- Brand names
- Thymoglobuline
- Other names
- FTM-ATG regimenTuebingen RIC regimen
02
Targets
RNR (Ribonucleotide reductase)LIG1 (DNA ligase 1)DNA polymerase familyDNA
Beyond the preview
Go deeper on fludarabine + thiotepa + melphalan + anti-thymocyte globulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fludarabine + thiotepa + melphalan + anti-thymocyte globulin.